Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Eidos Therapeutics Inc (NASDAQ: EIDX) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Eidos Therapeutics Inc (NASDAQ: EIDX) concerning whether a series of statements by Eidos Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On April 1, 2019, after the market closed, the Company filed a Form 8-K with the SEC announcing that its previously issued financial statements for the first three quarterly periods in the year ended December 31, 2018 could no longer be relied upon.

Based in San Francisco, California, and founded in 2013 Eidos Therapeutics Inc focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR).

If you purchased shares of Eidos Therapeutics Inc (NASDAQ: EIDX) on or before April 1, 2019, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185